ATTR amyloidosis, A for Amyloid and the TTR is an abbreviation used for the protein “transthyretin.” ATTR amyloidosis is a rare disease, caused by the build-up of abnormal protein deposits in various tissues of the body. Amyloid deposits cause disorder by damaging the structure and the function of the organs where they are found and they can affect almost any part of the body.
Browse Global Transthyretin Amyloidosis (ATTR) Market Report Details at: http://www.orbisresearch.com/reports/index/global-transthyretin-amyloidosis-attr-market-industry-analysis-and-outlook-2018-2025
There are three different types of ATTR Amyloidosis:
- Familial Amyloid Polyneuropathy (FAP), which affects the nervous system, often the heart and sometimes the kidneys and eyes. Second is,
- Familial Amyloid Cardiomyopathy (FAC), which is a hereditary, genetic condition, caused by mutations in the TTR gene resulting in production of the abnormal TTR
- Senile Systemic Amyloidosis (SSA) which is not hereditary and a slowly progressive disease. It is far more prevalent in men than in women.
Methods to diagnose ATTR include tissue biopsy, genetic testing and imaging studies of the heart.
Currently, there are no higher efficacy ATTR drugs available in the market, but they are expected to hit the market by 2018. The potential ATTR drug candidates include Patisiran and IONIS-TTRrx. For now, off-label drugs and therapies are employed to counter the progression of ATTR.
Request Sample of this Report at: http://www.orbisresearch.com/contacts/request-sample/366384
The global ATTR market is expected to experience robust growth post the launch of ATTR therapeutic drugs, primarily due to increasing African-American population, increasing health care expenditure and accelerating economic growth. However, the growth of this budding market is hindered by the stringent regulations, high cost of ATTR drugs, misdiagnosis of ATTR disorder and limitation of clinical trials.
The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report.
The four major players: Pfizer Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc. and Prothena Corporation Plc. are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global ATTR market along with the study of the regional markets.
Buy this Report at: http://www.orbisresearch.com/contact/purchase/366384
Points Covered in Table of Contents:
1. Overview
1.1 Introduction
1.2 Types
1.3 Diagnosis
1.4 Treatment
2. Global ATTR Market
2.1 Global ATTR Market Forecast by Patient Volume
2.2 Global ATTR Market Forecast by Treated Patient
2.3 Global ATTR Market Forecast by Value
2.4 Global ATTR Market Forecast by Drug Type
2.4.1 Global Patisiran Market Forecast by Value
2.4.2 Global IONIS-TTRrx Market Forecast by Value
2.5 Global ATTR Market Value by Region
3. Regional Market Analysis
3.1 The U.S.
3.1.1 The U.S. ATTR Market Forecast by Patient Volume
3.1.2 The U.S. ATTR Market Forecast by Treated Patient
3.1.3 The U.S. ATTR Market Forecast by Value
3.1.4 The U.S. Patisiran Market Forecast by Value
3.1.5 The U.S. IONIS-TTRrx Market Forecast by Value
3.2 Europe
3.2.1 Europe ATTR Market Forecast by Patient Volume
3.2.2 Europe ATTR Market Forecast by Treated Patient
3.2.3 Europe ATTR Market Forecast by Value
3.2.4 Europe Patisiran Market Forecast by Value
3.2.5 Europe IONIS-TTRrx Market Forecast by Value
3.3 ROW
3.3.1 ROW ATTR Market Forecast by Patient Volume
3.3.2 ROW ATTR Market Forecast by Treated Patient
3.3.3 ROW ATTR Market Forecast by Value
3.3.4 ROW Patisiran Market Forecast by Value
3.3.5 ROW IONIS-TTRrx Market Forecast by Value
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rise in African-American Population
4.1.2 Increasing HealthCare Expenditure
4.1.3 Accelerating Economic Growth
4.1.4 Development of Drug Therapies
4.2 Key Trends
4.2.1 Increasing Research & Development Efforts by Companies
4.2.2 Rising Public Awareness
4.3 Challenges
4.3.1 Stringent Regulations
4.3.2 High Cost of ATTR Drugs
4.3.3 Misdiagnosis of ATTR Disorder
4.3.4 Limitation of Clinical Trials
5. Competition
5.1 Global ATTR Market
5.1.1 Revenue Comparison of Key Companies
5.1.2 Market Cap Comparison of Key Companies
6. Company Profiles
6.1 Pfizer Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Ionis Pharmaceuticals Inc.
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Alnylam Pharmaceuticals, Inc.
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Prothena Corporation Plc.
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
Media Contact
Company Name: Orbis Research
Contact Person: Hector Costello
Email:Send Email
Phone: +1 (214) 884-6817
Address:4144N Central Expressway, Suite 600
City: Dallas
State: Texas
Country: United States
Website: http://www.orbisresearch.com/reports/index/global-transthyretin-amyloidosis-attr-market-industry-analysis-and-outlook-2018-2025
